World-renowned experts will guide the clinical development of ABS-201, a therapeutic antibody entering clinical trials for the treatment of androgenetic alopecia.VANCOUVER, Wash. and NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced that world-renowned dermatologists Dr. Rodney Sinclair and Dr. David Goldberg have joined its ABS-201 Scientific Advisory Board. They will guide the scientifi ...

Core Insights - Almirall and Absci Corporation are expanding their AI Drug Discovery collaboration to include a second target for dermatological indications, building on the success of their initial collaboration [1][2][4] - The collaboration leverages Absci's Integrated Drug Creation™ platform and Almirall's dermatology expertise to accelerate the development of innovative therapeutics for chronic skin diseases [2][3] - Absci is eligible for up to approximately $650 million in payments across both programs, in addition to royalties on potential product sales [3] Company Overview - Almirall is a global biopharmaceutical company focused on medical dermatology, founded in 1944 and headquartered in Barcelona, with total revenue of €990 million in 2024 and over 2000 employees globally [5][6] - Absci is a clinical-stage biopharmaceutical company that utilizes generative AI for drug discovery, aiming to create better biologics faster [8][9] Collaboration Details - The initial collaboration, announced in November 2023, successfully delivered AI-designed functional antibody leads against a difficult-to-drug target [2][4] - Absci's generative AI platform is combined with wet lab capabilities to design and validate therapeutic candidates, while Almirall leads the preclinical and clinical development [3][4] - The collaboration aims to accelerate innovation in dermatology by utilizing generative AI for new therapeutic approaches [4]

Core Insights - Absci Corporation has transitioned to a clinical-stage biopharmaceutical company with the initiation of Phase 1 trials for ABS-101, the first AI-designed biologic targeting inflammatory bowel disease (IBD) [1][2][3] Group 1: ABS-101 Development - ABS-101 is an investigational anti-TL1A antibody engineered using Absci's generative AI platform, demonstrating high potency and reduced immunogenicity risk, allowing for quarterly subcutaneous dosing [2][4] - The Phase 1 study is randomized, double-blind, and placebo-controlled, enrolling approximately 40 healthy adult participants to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) [2][3] - Interim safety, PK/PD, and immunogenicity data for ABS-101 are expected in the second half of 2025 [2][4] Group 2: Pipeline and Future Prospects - In addition to ABS-101, Absci is advancing ABS-201, an anti-prolactin receptor antibody for androgenetic alopecia, with Phase 1 trials anticipated to begin in early 2026 [3][6] - The company emphasizes the potential of its generative AI platform to accelerate the development of innovative therapeutics, aiming to bring better biologics to patients more quickly [3][5] Group 3: Company Overview - Absci utilizes an Integrated Drug Creation™ platform that combines AI models with synthetic biology to design therapeutics targeting challenging medical conditions [5][6] - The company is headquartered in Vancouver, WA, with additional facilities in New York City and Switzerland, and collaborates with various pharmaceutical and biotech partners to enhance its therapeutic pipeline [6]